Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Epizyme (NASDAQ: EPZM)

Organization & Developments: Epizyme

Parents

2011: Epizyme, Riding High on Two Big Pharma Deals, Zeroes in on Personalized Cancer Therapy (2011)
2011: Xconomy.com-Epizyme (2011)
2014: Epizyme starts trial of lead drug in childhood leukemia
2018: Epizyme Provides Update Regarding Tazemetostat Clinical Program_nasdaq
2018: Epizyme: An Updated Investment Thesis - Epizyme (NASDAQ:EPZM)
2019: Epizyme: Interesting, But Not For Us_seekingalpha.com
2020: Biotech Analysis Central Preview Series: Epizyme_seekingalpha.com
2021: Epizyme Comeback Is Likely, Price Makes It A Buy
2021: Reassessing Epizyme
2022: Ipsen to Acquire Epizyme - Growth in Oncology
Epizyme’s idea is to turn off the activity of a specific enzyme that basically makes it possible for multiple genes and proteins to spin out of control in cancer patients
Indication of enthusiasm for epigenetics, an emerging field of science that looks at how certain genes can be turned on or off without altering the underlying DNA.